JP2014508161A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014508161A5 JP2014508161A5 JP2013556833A JP2013556833A JP2014508161A5 JP 2014508161 A5 JP2014508161 A5 JP 2014508161A5 JP 2013556833 A JP2013556833 A JP 2013556833A JP 2013556833 A JP2013556833 A JP 2013556833A JP 2014508161 A5 JP2014508161 A5 JP 2014508161A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- independently
- present
- strand
- tlr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims 28
- 108020004999 messenger RNA Proteins 0.000 claims 26
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 claims 24
- 102100024333 Toll-like receptor 2 Human genes 0.000 claims 24
- 230000000692 anti-sense effect Effects 0.000 claims 24
- 239000002773 nucleotide Substances 0.000 claims 21
- 125000003729 nucleotide group Chemical group 0.000 claims 21
- 230000000295 complement effect Effects 0.000 claims 19
- 239000003112 inhibitor Substances 0.000 claims 19
- 108091081021 Sense strand Proteins 0.000 claims 18
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims 16
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims 16
- 208000019693 Lung disease Diseases 0.000 claims 9
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical group O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims 6
- 125000002652 ribonucleotide group Chemical group 0.000 claims 6
- DWRXFEITVBNRMK-JXOAFFINSA-N ribothymidine Chemical group O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JXOAFFINSA-N 0.000 claims 6
- 208000004852 Lung Injury Diseases 0.000 claims 5
- 206010069363 Traumatic lung injury Diseases 0.000 claims 5
- 231100000515 lung injury Toxicity 0.000 claims 5
- 210000004072 lung Anatomy 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000004055 small Interfering RNA Substances 0.000 claims 4
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Chemical group O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 3
- 239000000074 antisense oligonucleotide Substances 0.000 claims 3
- 238000012230 antisense oligonucleotides Methods 0.000 claims 3
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims 3
- 238000002054 transplantation Methods 0.000 claims 3
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims 3
- 229940045145 uridine Drugs 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 108700011259 MicroRNAs Proteins 0.000 claims 2
- 108091027967 Small hairpin RNA Proteins 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 101150076937 TLR2 gene Proteins 0.000 claims 2
- 101150082427 Tlr4 gene Proteins 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000002679 microRNA Substances 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 1
- 108010006654 Bleomycin Proteins 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 208000034706 Graft dysfunction Diseases 0.000 claims 1
- 208000004530 Primary Graft Dysfunction Diseases 0.000 claims 1
- 208000010285 Ventilator-Induced Lung Injury Diseases 0.000 claims 1
- 206010069351 acute lung injury Diseases 0.000 claims 1
- 229960001561 bleomycin Drugs 0.000 claims 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 230000002452 interceptive effect Effects 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161448723P | 2011-03-03 | 2011-03-03 | |
| US61/448,723 | 2011-03-03 | ||
| PCT/US2012/027169 WO2012118910A2 (en) | 2011-03-03 | 2012-03-01 | Compositions and methods for treating lung disease and injury |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014508161A JP2014508161A (ja) | 2014-04-03 |
| JP2014508161A5 true JP2014508161A5 (enExample) | 2015-04-16 |
| JP6000287B2 JP6000287B2 (ja) | 2016-09-28 |
Family
ID=45816001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013556833A Expired - Fee Related JP6000287B2 (ja) | 2011-03-03 | 2012-03-01 | 肺疾患および損傷を治療するための組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9205100B2 (enExample) |
| EP (1) | EP2681314B1 (enExample) |
| JP (1) | JP6000287B2 (enExample) |
| KR (1) | KR101937498B1 (enExample) |
| CN (1) | CN103492572A (enExample) |
| AU (1) | AU2012223365B2 (enExample) |
| CA (1) | CA2828002A1 (enExample) |
| IL (1) | IL228252A (enExample) |
| SG (1) | SG192961A1 (enExample) |
| WO (1) | WO2012118910A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010324658A1 (en) * | 2009-11-26 | 2012-05-03 | Quark Pharmaceuticals, Inc. | siRNA compounds comprising terminal substitutions |
| SG192961A1 (en) | 2011-03-03 | 2013-09-30 | Quark Pharmaceuticals Inc | Compositions and methods for treating lung disease and injury |
| ES2555160B1 (es) * | 2014-06-24 | 2016-10-25 | Aptus Biotech, S.L. | Aptámeros específicos de TLR-4 y usos de los mismos |
| US11072777B2 (en) | 2016-03-04 | 2021-07-27 | University Of Louisville Research Foundation, Inc. | Methods and compositions for ex vivo expansion of very small embryonic-like stem cells (VSELs) |
| AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
| WO2018191747A1 (en) | 2017-04-14 | 2018-10-18 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for treating pulmonary arterial hypertension |
| WO2018191751A1 (en) | 2017-04-14 | 2018-10-18 | Arizona Board Of Regents On Behalf Of The University Of Arizonia | Compositions and methods for treating pulmonary fibrosis |
| WO2020011869A2 (en) | 2018-07-11 | 2020-01-16 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting tlr2 |
| KR102562955B1 (ko) | 2021-07-08 | 2023-08-03 | 렉스소프트 주식회사 | 폐 기능 저하 위험 예측용 단일염기다형성 및 이의 용도 |
| CN114796273A (zh) * | 2022-07-01 | 2022-07-29 | 中国人民解放军总医院第一医学中心 | Tlr4激动的外泌体或外泌体制剂在制备防治放射性肺损伤药物中的应用 |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4501729A (en) | 1982-12-13 | 1985-02-26 | Research Corporation | Aerosolized amiloride treatment of retained pulmonary secretions |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4959217A (en) | 1986-05-22 | 1990-09-25 | Syntex (U.S.A.) Inc. | Delayed/sustained release of macromolecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4925678A (en) | 1987-04-01 | 1990-05-15 | Ranney David F | Endothelial envelopment drug carriers |
| US5080646A (en) | 1988-10-03 | 1992-01-14 | Alza Corporation | Membrane for electrotransport transdermal drug delivery |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| AU630076B2 (en) | 1987-09-21 | 1992-10-22 | Gen-Probe Incorporated | Non-nucleotide linking reagents for nucleotide probes |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| US5167616A (en) | 1989-12-14 | 1992-12-01 | Alza Corporation | Iontophoretic delivery method |
| US6153737A (en) | 1990-01-11 | 2000-11-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
| US5214136A (en) | 1990-02-20 | 1993-05-25 | Gilead Sciences, Inc. | Anthraquinone-derivatives oligonucleotides |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| US5138045A (en) | 1990-07-27 | 1992-08-11 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
| US6335434B1 (en) | 1998-06-16 | 2002-01-01 | Isis Pharmaceuticals, Inc., | Nucleosidic and non-nucleosidic folate conjugates |
| US5225182A (en) | 1991-10-31 | 1993-07-06 | Sharma Yash P | Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system |
| DK1695979T3 (da) | 1991-12-24 | 2011-10-10 | Isis Pharmaceuticals Inc | Gappede modificerede oligonukleotider |
| AU687736B2 (en) | 1992-05-11 | 1998-03-05 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting viral replication |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| EP0786522A2 (en) | 1992-07-17 | 1997-07-30 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecules for treatment of stenotic conditions |
| US6235886B1 (en) | 1993-09-03 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Methods of synthesis and use |
| WO1995006731A2 (en) | 1993-09-02 | 1995-03-09 | Ribozyme Pharmaceuticals, Inc. | Non-nucleotide containing enzymatic nucleic acid |
| DE69433036T2 (de) | 1993-09-03 | 2004-05-27 | Isis Pharmaceuticals, Inc., Carlsbad | Aminoderivatisierte nukleoside und oligonukleoside |
| US5624803A (en) | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
| EP0725788B1 (en) | 1993-10-27 | 1998-12-16 | Ribozyme Pharmaceuticals, Inc. | 2'-amido and 2'-peptido modified oligonucleotides |
| US6051256A (en) | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
| US6447796B1 (en) | 1994-05-16 | 2002-09-10 | The United States Of America As Represented By The Secretary Of The Army | Sustained release hydrophobic bioactive PLGA microspheres |
| CA2207593A1 (en) | 1994-12-13 | 1996-06-20 | John Gustofson | Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6251666B1 (en) | 1997-03-31 | 2001-06-26 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid catalysts comprising L-nucleotide analogs |
| US6235310B1 (en) | 1997-04-04 | 2001-05-22 | Valentis, Inc. | Methods of delivery using cationic lipids and helper lipids |
| US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
| TW589189B (en) | 1997-08-04 | 2004-06-01 | Scras | Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis |
| KR100414936B1 (ko) | 1997-09-12 | 2004-01-13 | 엑시콘 에이/에스 | 이환 및 삼환 뉴클레오시드, 뉴클레오타이드 및올리고뉴클레오타이드 동족체 |
| US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
| EP1038016A2 (en) | 1997-12-16 | 2000-09-27 | Valentis Inc. | Needle-free injection of formulated nucleic acid molecules |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| EP2138191A1 (en) | 1998-01-05 | 2009-12-30 | University Of Washington | Enhanced transport using membrane disruptive agents |
| AR020078A1 (es) | 1998-05-26 | 2002-04-10 | Syngenta Participations Ag | Metodo para alterar la expresion de un gen objetivo en una celula de planta |
| GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
| EP1096921B1 (en) | 1998-07-20 | 2003-04-16 | Protiva Biotherapeutics Inc. | Liposomal encapsulated nucleic acid-complexes |
| WO2000044914A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| NZ513402A (en) | 1999-02-12 | 2003-06-30 | Sankyo Co | Novel nucleosides and oligonucleotide analogues |
| EP1159441B8 (en) | 1999-03-10 | 2008-10-29 | Marie Curie Cancer Care | Delivery of nucleic acids and proteins to cells |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| EP1309726B2 (en) | 2000-03-30 | 2018-10-03 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
| AU2001281730A1 (en) | 2000-07-26 | 2002-02-05 | Chemometec A/S | Spatially resolved enzyme-linked assay |
| US20020130430A1 (en) | 2000-12-29 | 2002-09-19 | Castor Trevor Percival | Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products |
| WO2002087541A1 (en) | 2001-04-30 | 2002-11-07 | Protiva Biotherapeutics Inc. | Lipid-based formulations for gene transfer |
| US6586524B2 (en) | 2001-07-19 | 2003-07-01 | Expression Genetics, Inc. | Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier |
| US20040063654A1 (en) | 2001-11-02 | 2004-04-01 | Davis Mark E. | Methods and compositions for therapeutic use of RNA interference |
| AUPR894201A0 (en) | 2001-11-19 | 2001-12-13 | Women's And Children's Hospital | Respiratory delivery for gene therapy and lentiviral delivery particle |
| US7060498B1 (en) | 2001-11-28 | 2006-06-13 | Genta Salus Llc | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
| US7141540B2 (en) | 2001-11-30 | 2006-11-28 | Genta Salus Llc | Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof |
| ES2280826T5 (es) | 2002-08-05 | 2017-08-03 | Silence Therapeutics Gmbh | Nuevas formas adicionales de moléculas de ARN de interferencia |
| WO2004014933A1 (en) | 2002-08-07 | 2004-02-19 | University Of Massachusetts | Compositions for rna interference and methods of use thereof |
| ES2576677T3 (es) | 2003-03-21 | 2016-07-08 | Roche Innovation Center Copenhagen A/S | Análogos de ARN interfirientes cortos |
| US20050136437A1 (en) | 2003-08-25 | 2005-06-23 | Nastech Pharmaceutical Company Inc. | Nanoparticles for delivery of nucleic acids and stable double-stranded RNA |
| WO2005085443A2 (en) * | 2004-03-01 | 2005-09-15 | Massachusetts Institute Of Technology | Rnai-based therapeutics for allergic rhinitis and asthma |
| US20070265220A1 (en) | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| JP5243789B2 (ja) | 2004-03-15 | 2013-07-24 | シティ・オブ・ホープ | 二本鎖ｒｎａによる遺伝子発現の特異的阻害のための方法及び組成物 |
| US7081836B2 (en) | 2004-07-09 | 2006-07-25 | The Johns Hopkins University | Method and apparatus for covertly detecting and reporting a distress condition in a vehicle control cabin |
| US7358223B2 (en) | 2004-10-04 | 2008-04-15 | Nitto Denko Corporation | Biodegradable cationic polymers |
| WO2006047842A2 (en) | 2004-11-08 | 2006-05-11 | K.U. Leuven Research And Development | Modified nucleosides for rna interference |
| PT2730277T (pt) | 2004-12-22 | 2020-04-21 | Nitto Denko Corp | Veículo de fármaco e kit de veículo de fármaco para a inibição da fibrose |
| AU2006297259A1 (en) * | 2005-09-30 | 2007-04-12 | Oklahoma Medical Research Foundation | Regulation of toll-like receptors on stem cells |
| US8362229B2 (en) | 2006-02-08 | 2013-01-29 | Quark Pharmaceuticals, Inc. | Tandem siRNAS |
| EP1881080A1 (en) * | 2006-07-18 | 2008-01-23 | Institut Gustave Roussy | Toll like receptor 4 dysfunction and the biological applications thereof |
| JP2010507387A (ja) * | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | 新規のｓｉＲＮＡおよびその使用方法 |
| US20100215588A1 (en) * | 2007-04-26 | 2010-08-26 | Rami Skaliter | Therapeutic delivery of inhibitory nucleic acid molecules to the respiratory system |
| WO2008154008A1 (en) * | 2007-06-11 | 2008-12-18 | The Scripps Research Institute | Methods and compositions for inhibiting toll-like receptor mediated immune responses |
| WO2009015107A1 (en) * | 2007-07-20 | 2009-01-29 | Yeda Research And Development Co. Ltd. | Modulation of toll-like receptors for controlling neurogenesis |
| AU2008285626B2 (en) | 2007-08-03 | 2013-09-12 | Neuramedy Co., Ltd. | Use of TLR-2 antagonists for treatment of reperfusion injury and tissue damage |
| MX2011004674A (es) | 2008-11-04 | 2011-05-25 | Idera Pharmaceuticals Inc | Modulacion de la expresion del receptor 4 tipo larga distancia por oligonucleotidos antisentido. |
| KR20110081336A (ko) | 2008-11-04 | 2011-07-13 | 이데라 파마슈티칼즈, 인코포레이티드 | 안티센스 올리고누클레오티드에 의한 ｔｏｌｌ―유사 수용체 2 발현의 조절 |
| SG175133A1 (en) * | 2009-04-09 | 2011-12-29 | Univ North Carolina | Methods of treating edema related to ischemia-reperfusion |
| GB0908425D0 (en) | 2009-05-15 | 2009-06-24 | Medical Res Council | Medical use |
| AU2010324658A1 (en) | 2009-11-26 | 2012-05-03 | Quark Pharmaceuticals, Inc. | siRNA compounds comprising terminal substitutions |
| SG192961A1 (en) | 2011-03-03 | 2013-09-30 | Quark Pharmaceuticals Inc | Compositions and methods for treating lung disease and injury |
| AU2012223366B2 (en) | 2011-03-03 | 2017-02-23 | Quark Pharmaceuticals, Inc. | Oligonucleotide modulators of the toll-like receptor pathway |
-
2012
- 2012-03-01 SG SG2013064696A patent/SG192961A1/en unknown
- 2012-03-01 US US14/002,660 patent/US9205100B2/en not_active Expired - Fee Related
- 2012-03-01 CN CN201280020499.1A patent/CN103492572A/zh active Pending
- 2012-03-01 WO PCT/US2012/027169 patent/WO2012118910A2/en not_active Ceased
- 2012-03-01 AU AU2012223365A patent/AU2012223365B2/en not_active Ceased
- 2012-03-01 EP EP12708474.7A patent/EP2681314B1/en not_active Not-in-force
- 2012-03-01 KR KR1020137025288A patent/KR101937498B1/ko not_active Expired - Fee Related
- 2012-03-01 JP JP2013556833A patent/JP6000287B2/ja not_active Expired - Fee Related
- 2012-03-01 CA CA2828002A patent/CA2828002A1/en not_active Abandoned
-
2013
- 2013-09-02 IL IL228252A patent/IL228252A/en active IP Right Grant
-
2015
- 2015-10-28 US US14/924,993 patent/US9822362B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014508161A5 (enExample) | ||
| CN103080314B (zh) | 显性突变基因表达抑制剂 | |
| JP2014509511A5 (enExample) | ||
| ES2556128T3 (es) | ARN interfiriente pequeño internamente segmentado | |
| JP2013511990A5 (enExample) | ||
| JP2013535212A5 (enExample) | ||
| JP2015109851A5 (enExample) | ||
| JP2014518612A5 (enExample) | ||
| JP2016530882A5 (enExample) | ||
| JP2014527401A5 (enExample) | ||
| JP2009514877A5 (enExample) | ||
| JP2015523855A5 (enExample) | ||
| JP2020500929A5 (enExample) | ||
| JP2018516091A5 (enExample) | ||
| JP2016116520A5 (enExample) | ||
| JP2013514761A5 (enExample) | ||
| JP2016513976A5 (enExample) | ||
| JP2009535045A5 (enExample) | ||
| ES2865030T3 (es) | Estructuras de ARNip para una alta actividad y una inespecificidad reducida | |
| CN110832077B (zh) | 用于抑制α-ENaC表达的RNAi剂及使用方法 | |
| JP2017516461A (ja) | 遺伝子サイレンシングにおいて低下したｏｆｆ−ｔａｒｇｅｔ効果を有するｕｎａオリゴマー | |
| US20180223280A1 (en) | Nucleic acid complex | |
| JPWO2018003739A1 (ja) | 機能的リガンドを含む核酸複合体 | |
| WO2012174224A2 (en) | Methods for administering nucleic acid-based therapeutics | |
| CN108367021A (zh) | 包含硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法 |